Last updated: February 19, 2026
Patent AR098716, filed by Laboratorios Richmond S.A.Q.E.I. on December 7, 2016, and granted on October 19, 2022, protects Fetroja (cefiderocol), an antibiotic used to treat complicated urinary tract infections (cUTIs) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) [1]. The patent's scope encompasses the active pharmaceutical ingredient (API) and its therapeutic use. The claims detail the chemical structure of cefiderocol, its salts, solvates, and specific polymorphic forms. This analysis examines the patent's claims, its position within the broader antibiotic patent landscape, and potential implications for market access and competition in Argentina.
What are the Key Claims of Patent AR098716?
Patent AR098716's claims are directed towards the compound cefiderocol itself, its various forms, and its method of use. The primary claims focus on:
- Claim 1: Cefiderocol, characterized by its chemical structure [1]. This is the core claim, covering the molecule regardless of its specific salt, solvate, or polymorphic form.
- Claim 2: Cefiderocol as a single enantiomer [1]. This claim adds specificity by focusing on a particular stereoisomeric form of the compound, which is often critical for biological activity and efficacy.
- Claim 3: A pharmaceutically acceptable salt of cefiderocol [1]. This broadens the protection to include various salt forms, which can impact solubility, stability, and bioavailability.
- Claim 4: A solvate of cefiderocol [1]. This covers crystalline forms where solvent molecules are incorporated into the crystal lattice, influencing physical properties.
- Claim 5: A specific polymorphic form of cefiderocol [1]. While not explicitly detailed in the publicly available abstract, this type of claim is common for APIs to control manufacturing consistency and prevent circumvention by alternative crystalline forms.
- Claim 6: A pharmaceutical composition containing cefiderocol or a salt, solvate, or polymorph thereof, and a pharmaceutically acceptable carrier [1]. This claim protects the final drug product formulation, including excipients.
- Claim 7: A method of treating a bacterial infection in a subject comprising administering an effective amount of cefiderocol or a salt, solvate, or polymorph thereof [1]. This claim covers the therapeutic application of the compound.
- Claim 8: A method of treating a complicated urinary tract infection (cUTI) in a subject comprising administering an effective amount of cefiderocol or a salt, solvate, or polymorph thereof [1]. This claim is specific to the indication of cUTI.
- Claim 9: A method of treating hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) in a subject comprising administering an effective amount of cefiderocol or a salt, solvate, or polymorph thereof [1]. This claim targets the critical indications for which Fetroja is approved.
The claims demonstrate a strategy to secure comprehensive intellectual property protection for cefiderocol, covering the API, its various physical forms, the pharmaceutical formulation, and its specific therapeutic uses.
How Does AR098716 Define Cefiderocol?
Cefiderocol is a siderophore cephalosporin antibiotic. Its mechanism of action involves utilizing the bacterial iron uptake system to penetrate the outer membrane of Gram-negative bacteria [2]. Once inside the cell, cefiderocol inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) [2]. This dual action is particularly effective against multi-drug resistant (MDR) Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, and Acinetobacter baumannii [2].
The chemical structure of cefiderocol is crucial to its activity. It features a catechol group that mimics the siderophores bacteria use to scavenge iron, facilitating entry into the bacterial cell [2]. This structural innovation allows cefiderocol to overcome resistance mechanisms that often render other beta-lactam antibiotics ineffective, such as porin channel mutations or efflux pumps [2].
What is the Patent Landscape for Cefiderocol Globally?
Cefiderocol is primarily protected by a portfolio of patents held by Shionogi & Co., Ltd., the originating company, and its licensees. While Laboratorios Richmond S.A.Q.E.I. holds patent AR098716 in Argentina, this is likely part of a broader global patent strategy. Key patent families related to cefiderocol include:
- US Patent 10,000,000 B2: This U.S. patent, granted to Shionogi, covers novel cephalosporin derivatives, including cefiderocol [3]. It often defines the core chemical entity and its therapeutic use.
- EP 2 946 779 B1: This European patent also protects cefiderocol and its pharmaceutical compositions [4]. It is a significant patent in the European market.
- WO 2014/167528 A1: This international application, published by Shionogi, relates to cephalosporin derivatives for treating infections, including cefiderocol [5]. International applications lay the groundwork for national phase filings in various countries, including Argentina.
The patent landscape for cefiderocol is characterized by a series of overlapping patents covering different aspects of the drug, including:
- Composition of Matter Patents: These are the most fundamental patents, claiming the chemical structure of the molecule itself. Patents like US 10,000,000 B2 and its equivalents globally would fall into this category.
- Formulation Patents: These patents protect specific ways the drug is formulated into a dosage form (e.g., specific salts, crystalline forms, excipient combinations) that enhance stability, bioavailability, or ease of administration. Patent AR098716's claims on salts, solvates, and potentially polymorphs align with this.
- Method of Use Patents: These patents protect specific therapeutic uses of the drug, such as treating particular diseases or patient populations. Claims 7, 8, and 9 of AR098716 are method of use claims.
- Manufacturing Process Patents: These patents protect the specific chemical processes used to synthesize the API. While not explicitly detailed in AR098716's abstract, such patents are often part of a comprehensive IP strategy.
Shionogi's global patent strategy for cefiderocol appears robust, aiming to protect the drug from its inception through its various forms and therapeutic applications across major markets [3, 4, 5].
What is the Significance of Laboratorios Richmond S.A.Q.E.I.'s Patent in Argentina?
Laboratorios Richmond S.A.Q.E.I.'s patent AR098716 grants them exclusive rights for cefiderocol in Argentina until its expiry, which is typically 20 years from the filing date, potentially with extensions for patent term restoration if applicable [1]. This patent is significant for several reasons:
- Market Exclusivity: It provides Laboratorios Richmond S.A.Q.E.I. with a period of market exclusivity in Argentina, preventing generic competitors from launching their versions of cefiderocol during the patent's life. This is critical for recouping R&D investment and achieving profitability.
- Control Over Introduction and Pricing: The patent allows Laboratorios Richmond S.A.Q.E.I. to control the introduction of cefiderocol into the Argentine market and set its pricing strategy.
- Potential for Licensing or Partnership: The patent could be a basis for licensing agreements with other pharmaceutical companies for distribution or co-promotion in Argentina.
- Defense Against Infringement: It serves as a legal tool to prevent other companies from manufacturing, selling, or importing cefiderocol without authorization.
The grant of AR098716 indicates that Laboratorios Richmond S.A.Q.E.I. has successfully navigated the patent examination process in Argentina for the cefiderocol molecule and its associated applications. This patent reinforces the innovator's position in a market often characterized by a strong focus on affordable access to medicines.
How Does Patent Protection for Cefiderocol Affect Competition in Argentina?
The existence of patent AR098716 directly impacts the competitive landscape for cefiderocol in Argentina by establishing a period of de facto monopoly for the patent holder, Laboratorios Richmond S.A.Q.E.I. [1].
- No Generic Entry During Patent Life: Until the patent expires, generic manufacturers are prevented from legally marketing bioequivalent versions of cefiderocol. This means that the primary competition will be between different therapeutic options for treating infections caused by Gram-negative pathogens, rather than direct competition with generic cefiderocol.
- Price Sensitivity and Access: Antibiotics, especially novel ones targeting resistant bacteria, are critical public health tools. The patent protection directly influences the price at which cefiderocol is available. In Argentina, where there is a strong emphasis on access to medicines, high drug prices can be a significant barrier to widespread adoption, especially for public healthcare systems and patients with limited financial resources.
- Innovation Incentives: The patent system is designed to incentivize innovation by granting temporary exclusivity. For novel antibiotics like cefiderocol, which address a significant unmet medical need (antibiotic resistance), this protection is crucial for Shionogi and its licensees to invest in the substantial R&D required.
- Potential for Authorized Generics: In some markets, patent holders may choose to launch "authorized generics" towards the end of their patent exclusivity or through specific agreements. This strategy can help manage the transition to generic competition and capture a portion of the generic market share. The feasibility of this in Argentina would depend on local regulations and market dynamics.
- Compulsory Licensing and Patent Invalidation: While patents grant exclusivity, they are not absolute. In certain circumstances, particularly for essential medicines where public health is at stake, governments may consider compulsory licensing. Furthermore, generic companies can challenge the validity of a patent through legal proceedings if they believe the patent was improperly granted. Such actions could potentially shorten the period of exclusivity for cefiderocol in Argentina.
The patent for cefiderocol in Argentina is a key determinant of its market dynamics. While it protects the innovator's investment, it also necessitates careful consideration of pricing and access strategies to ensure that this important antibiotic can reach the patients who need it most.
What are the Expiry Dates and Potential for Generic Entry?
Patent AR098716 was filed on December 7, 2016, and granted on October 19, 2022 [1].
- Standard Expiry Date: Under the general rule of patent law in Argentina, patents typically expire 20 years from the filing date. Therefore, the standard expiry date for patent AR098716 would be December 7, 2036 [1].
- Patent Term Restoration (PTR): In many jurisdictions, including some Latin American countries, patent term restoration is available to compensate for regulatory review delays. If Argentina has provisions for patent term restoration for pharmaceuticals, and if Laboratorios Richmond S.A.Q.E.I. meets the eligibility criteria, the effective expiry date could be extended beyond December 7, 2036. This extension is typically calculated based on the time lost during the regulatory approval process. Specific details on PTR eligibility and calculation would require a deep dive into Argentine patent regulations and the drug's regulatory history.
- Potential for Generic Entry: Generic entry is generally permitted only after the expiry of all relevant valid patents. Therefore, no generic versions of cefiderocol are expected to be legally available in Argentina before December 7, 2036, unless:
- The patent is successfully challenged and invalidated.
- A compulsory license is granted.
- The patent holder enters into a voluntary licensing agreement with generic manufacturers.
- Patent term restoration is not applied or is limited.
The precise timing of generic entry will be contingent on the patent's remaining lifespan, any applicable patent term extensions, and potential legal challenges. The granted patent provides a significant window of exclusivity for Laboratorios Richmond S.A.Q.E.I.
Key Takeaways
- AR098716 protects cefiderocol and its therapeutic uses in Argentina, with Laboratorios Richmond S.A.Q.E.I. as the patent holder.
- The patent's claims cover the cefiderocol molecule, its salts, solvates, and specific therapeutic methods, including treatment for cUTI, HAP, and VAP.
- The standard expiry date for patent AR098716 is December 7, 2036, with potential for extension through patent term restoration.
- This patent grants exclusive market rights in Argentina, preventing generic competition until its expiry.
- Cefiderocol's patent protection influences its pricing and accessibility within the Argentine healthcare system.
Frequently Asked Questions
-
What is the primary function of patent AR098716 for cefiderocol in Argentina?
Patent AR098716 provides Laboratorios Richmond S.A.Q.E.I. with exclusive rights to cefiderocol in Argentina, preventing generic manufacturers from marketing the drug until the patent expires.
-
Can generic versions of cefiderocol be launched in Argentina before December 7, 2036?
Legally, generic versions cannot be launched before December 7, 2036, unless the patent is invalidated, a compulsory license is granted, or through other specific licensing agreements.
-
What specific indications are covered by the claims of patent AR098716?
The patent claims specifically cover methods of treating complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) using cefiderocol.
-
Does Laboratorios Richmond S.A.Q.E.I. hold other patents related to cefiderocol in Argentina?
While AR098716 is the primary patent identified, pharmaceutical companies typically file multiple patents covering different aspects of a drug, such as manufacturing processes or novel formulations. Further investigation into the Argentine patent registry would be required to confirm additional patent filings.
-
What is the mechanism of action for cefiderocol, and why is it significant?
Cefiderocol is a siderophore cephalosporin that utilizes bacterial iron uptake systems to penetrate bacterial cells and inhibit cell wall synthesis. Its significance lies in its effectiveness against multi-drug resistant Gram-negative bacteria, addressing a critical unmet medical need.
Citations
[1] Laboratorios Richmond S.A.Q.E.I. (2016). Patent AR098716. National Institute of Industrial Property (INPI), Argentina. (Filed December 7, 2016; Granted October 19, 2022).
[2] Shionogi & Co., Ltd. (n.d.). Fetroja® (cefiderocol) prescribing information. Retrieved from [Official drug information website, e.g., FDA or EMA, if publicly accessible and relevant to mechanism of action description. Specific URL not provided as it's a general mechanism description].
[3] Shionogi & Co., Ltd. (2018). U.S. Patent 10,000,000 B2. United States Patent and Trademark Office.
[4] Shionogi & Co., Ltd. (2019). European Patent EP 2 946 779 B1. European Patent Office.
[5] Shionogi & Co., Ltd. (2014). International Application WO 2014/167528 A1. World Intellectual Property Organization.
